LIVIVO - Search results -

Search results

Result 1 - 10 of total 276

Search options

Article ; Online: Emerging Nano‐Immunotherapeutic Approaches to Glioma

Jin Nan / Wei Yang / Yujie Xie / Meihua Yu / Yu Chen / Jun Zhang

Small Structures, Vol 4, Iss 8, Pp n/a-n/a (2023)

2023

Abstract: ... development of immunotherapeutic approaches is discussed, such as therapeutic glioma vaccines, dendritic cell ... and therapeutic approaches. The breakthrough discoveries in oncoimmunology have led to innovative and ... enabled glioma immunotherapy in preclinical and clinical studies is clarified and perspectives on future ...

Abstract	Glioma is a highly invasive and frequently occurring type of brain malignancy in the central nervous system. The prognosis is often poor for glioma patients, despite the substantial advances in diagnosis and therapeutic approaches. The breakthrough discoveries in oncoimmunology have led to innovative and efficacious immunotherapeutic strategies to treat or even cure cancer patients; however, the efficacy of immunotherapy to glioma is disappointing. The unsatisfied outcomes can be explained by local immune resistance, blood–brain barrier (BBB), spatially heterogenous and immunologically specialized glioma microenvironment, etc. The emergence of nanoengineered immunotherapeutics transforms the modalities in glioma immunotherapy under preclinical and clinical settings. Nanotechnology aids the immunotherapeutics crossing the BBB and flicks the switch of immunity locally and systematically for enhanced tumor‐infiltrating effector immune cells against glioma. Herein, the advancement of knowledge in healthy brain immunology and glioma‐associated local and systemic immunosuppression is summarized and highlighted. The clinical development of immunotherapeutic approaches is discussed, such as therapeutic glioma vaccines, dendritic cell vaccines, immune checkpoint blockade, adoptive cell therapy, and new immunotargets. Herein, nanotechnology‐enabled glioma immunotherapy in preclinical and clinical studies is clarified and perspectives on future possibilities of advancing nanoengineered immunotherapeutics to clinical reality for glioma treatment are provided.
Keywords	cancer immunotherapy ; combination therapy ; glioma treatment ; immunotherapeutic drug ; nanotechnology ; Physics ; QC1-999 ; Chemistry ; QD1-999
Subject code	610
Language	English
Publishing date	2023-08-01T00:00:00Z
Publisher	Wiley-VCH
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Current immunotherapeutic approaches to diffuse intrinsic pontine glioma.

Lin, Catherine / Smith, Christian / Rutka, James

Frontiers in genetics

2024 Volume 15, Page(s) 1349612

Abstract: Diffuse intrinsic pontine glioma (DIPG) is an aggressive brain tumour that occurs in the pons ...

Abstract	Diffuse intrinsic pontine glioma (DIPG) is an aggressive brain tumour that occurs in the pons of the brainstem and accounts for over 80% of all brainstem gliomas. The median age at diagnosis is 6-7 years old, with less than 10% overall survival 2 years after diagnosis and less than 1% after 5 years. DIPGs are surgically inaccessible, and radiation therapy provides only transient benefit, with death ensuing from relentless local tumour infiltration. DIPGs are now the leading cause of brain tumour deaths in children, with a societal cancer burden in years of life lost (YLL) of more than 67 per individual,
Language	English
Publishing date	2024-05-07
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2606823-0
ISSN	1664-8021
ISSN	1664-8021
DOI	10.3389/fgene.2024.1349612
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article: Immunotherapeutic approaches for glioma.

Okada, Hideho / Kohanbash, Gary / Zhu, Xinmei / Kastenhuber, Edward R / Hoji, Aki / Ueda, Ryo / Fujita, Mitsugu

Critical reviews in immunology

2009 Volume 29, Issue 1, Page(s) 1–42

Abstract: The development of effective immunotherapy strategies for glioma requires adequate understanding ... suggest novel mechanisms that may significantly improve the efficacy of immunotherapy against gliomas ... novel immunotherapy strategies that have been recently tested in non-CNS tumors and show great potential ...

Abstract	The development of effective immunotherapy strategies for glioma requires adequate understanding of the unique immunological microenvironment in the central nervous system (CNS) and CNS tumors. Although the CNS is often considered to be an immunologically privileged site and poses unique challenges for the delivery of effector cells and molecules, recent advances in technology and discoveries in CNS immunology suggest novel mechanisms that may significantly improve the efficacy of immunotherapy against gliomas. In this review, we first summarize recent advances in the CNS and CNS tumor immunology. We address factors that may promote immune escape of gliomas. We also review advances in passive and active immunotherapy strategies for glioma, with an emphasis on lessons learned from recent early-phase clinical trials. We also discuss novel immunotherapy strategies that have been recently tested in non-CNS tumors and show great potential for application to gliomas. Finally, we discuss how each of these promising strategies can be combined to achieve clinical benefit for patients with gliomas.
MeSH term(s)	Animals ; Central Nervous System/immunology ; Central Nervous System Neoplasms/immunology ; Central Nervous System Neoplasms/therapy ; Cytokines/immunology ; Cytokines/metabolism ; Dendritic Cells/immunology ; Dendritic Cells/metabolism ; Glioma/immunology ; Glioma/therapy ; Humans ; Immunotherapy/methods ; Suppressor Factors, Immunologic/immunology ; Suppressor Factors, Immunologic/metabolism ; T-Lymphocyte Subsets/immunology ; T-Lymphocyte Subsets/metabolism
Chemical Substances	Cytokines ; Suppressor Factors, Immunologic
Language	English
Publishing date	2009-04-08
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Review
ZDB-ID	1353116-5
ISSN	1040-8401
ISSN	1040-8401
DOI	10.1615/critrevimmunol.v29.i1.10
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1699: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Novel immunotherapeutic approaches to glioma.

Yamanaka, Ryuya

Current opinion in molecular therapeutics

2006 Volume 8, Issue 1, Page(s) 46–51

Abstract: ... as an approach to successfully induce an antitumor immune response and increase survival in patients with glioma ... immunotherapy for glioma patients. Dendritic cell- and peptide-based immunotherapy strategies appear promising ... with malignant glioma is poor. Therefore, the development of a new treatment modality is extremely important. There are ...

Abstract	Despite advances in radiation, chemotherapy and surgical resectioning, the prognosis of patients with malignant glioma is poor. Therefore, the development of a new treatment modality is extremely important. There are an increasing number of reports that systemic immunotherapy using dendritic cells and peptides is capable of inducing an anti-glioma response. This review highlights progress in dendritic cell- and peptide-based immunotherapy for glioma patients. Dendritic cell- and peptide-based immunotherapy strategies appear promising as an approach to successfully induce an antitumor immune response and increase survival in patients with glioma; the therapy appears to be safe and without major side effects. Biotherapy for malignant glioma with dendritic cells and peptides represents a novel treatment paradigm.
MeSH term(s)	Antigens, Neoplasm/immunology ; Cancer Vaccines/immunology ; Cancer Vaccines/therapeutic use ; Clinical Trials as Topic ; Dendritic Cells/immunology ; Glioma/immunology ; Glioma/therapy ; Humans ; Immunotherapy/methods ; Immunotherapy/trends
Chemical Substances	Antigens, Neoplasm ; Cancer Vaccines
Language	English
Publishing date	2006-02
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2022273-7
ISSN	1464-8431
ISSN	1464-8431
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5272: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms-a review.

Regmi, Moksada / Wang, Yingjie / Liu, Weihai / Dai, Yuwei / Liu, Shikun / Ma, Ke / Lin, Guozhong / Yang, Jun / Liu, Hongyi / Wu, Jian / Yang, Chenlong

Journal of experimental & clinical cancer research : CR

2024 Volume 43, Issue 1, Page(s) 47

Abstract: ... toward immunomodulation in glioma treatment. We dissect critical discoveries in immunotherapy, such as spotlighting ... maps the current landscape but also provides a blueprint for refining immunotherapy for glioma ... of our review is its exhaustive approach, synthesizing current research to elucidate the intricate roles ...

Abstract	In tumor therapeutics, the transition from conventional cytotoxic drugs to targeted molecular therapies, such as those targeting receptor tyrosine kinases, has been pivotal. Despite this progress, the clinical outcomes have remained modest, with glioblastoma patients' median survival stagnating at less than 15 months. This underscores the urgent need for more specialized treatment strategies. Our review delves into the progression toward immunomodulation in glioma treatment. We dissect critical discoveries in immunotherapy, such as spotlighting the instrumental role of tumor-associated macrophages, which account for approximately half of the immune cells in the glioma microenvironment, and myeloid-derived suppressor cells. The complex interplay between tumor cells and the immune microenvironment has been explored, revealing novel therapeutic targets. The uniqueness of our review is its exhaustive approach, synthesizing current research to elucidate the intricate roles of various molecules and receptors within the glioma microenvironment. This comprehensive synthesis not only maps the current landscape but also provides a blueprint for refining immunotherapy for glioma, signifying a paradigm shift toward leveraging immune mechanisms for improved patient prognosis.
MeSH term(s)	Humans ; Glioma/pathology ; Glioblastoma/pathology ; Immunotherapy ; Immunomodulation ; Myeloid-Derived Suppressor Cells ; Tumor Microenvironment ; Brain Neoplasms/drug therapy
Language	English
Publishing date	2024-02-12
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	803138-1
ISSN	1756-9966 ; 0392-9078
ISSN (online)	1756-9966
ISSN	0392-9078
DOI	10.1186/s13046-024-02973-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2065: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Current Immunotherapeutic Approaches for Malignant Gliomas.

Han, Myung-Hoon / Kim, Choong Hyun

Brain tumor research and treatment

2022 Volume 10, Issue 1, Page(s) 1–11

Abstract: ... of malignant glioma to immunotherapy. Despite centuries of efforts, immunotherapeutic successes for malignant glioma ... for malignant glioma includes monoclonal antibody-mediated immunotherapy, cytokine-mediated therapy, and ... drawn interest in immunotherapy for treatment of malignant glioma. There have been extensive attempts ...

Abstract	Glioblastoma is the most common malignant central nervous system (CNS) tumor (48.3%), with a median survival of only about 14.6 months. Although the CNS is an immune-privileged site, activated T cells can cross the blood-brain barrier. The recent successes of several immunotherapies for various cancers have drawn interest in immunotherapy for treatment of malignant glioma. There have been extensive attempts to evaluate the efficiency of immunotherapy against malignant glioma. Passive immunotherapy for malignant glioma includes monoclonal antibody-mediated immunotherapy, cytokine-mediated therapy, and adoptive cell transfer, also known as chimeric antigen receptor T cell treatment. On the other hand, active immunotherapy, which stimulates the patient's adaptive immune system against specific tumor-associated antigens, includes cancer vaccines that are divided into peptide vaccines and cell-based vaccines. In addition, there is immune checkpoint blockade therapy, which increases the efficiency of immunotherapy by reducing the resistance of malignant glioma to immunotherapy. Despite centuries of efforts, immunotherapeutic successes for malignant glioma remain limited. However, many clinical trials of adoptive cell transfer immunotherapy on malignant glioma are ongoing, and the outcomes are eagerly awaited. In addition, although there are still several obstacles, current clinical trials using personalized neoantigen-based dendritic cell vaccines offer new hope to glioblastoma patients. Furthermore, immune checkpoint targeted therapy is expected to decipher the mechanism of immunotherapy resistance in malignant glioma in the near future. More studies are needed to increase the efficacy of immunotherapy in malignant glioma. We hope that immunotherapy will become a new treatment of malignant glioma.
Language	English
Publishing date	2022-02-03
Publishing country	Korea (South)
Document type	Journal Article ; Review
ZDB-ID	3018737-0
ISSN	2288-2413 ; 2288-2405
ISSN (online)	2288-2413
ISSN	2288-2405
DOI	10.14791/btrt.2022.10.e25
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Wnt signaling: Modulating tumor-associated macrophages and related immunotherapeutic insights.

Yuan, Yimeng / Wu, Dapeng / Hou, Yifan / Zhang, Yi / Tan, Cong / Nie, Xiaobo / Zhao, Zhenhua / Hou, Junqing

Biochemical pharmacology

2024 Volume 223, Page(s) 116154

Abstract: ... therapy with conventional or immune therapies is a promising therapeutic approach and can facilitate ... in the tumor microenvironment (TME) and potentially impact the efficacy of cancer immunotherapy. In this review, we summarize ... gastric, hepatocellular, breast, thyroid, prostate, kidney, and lung cancers; osteosarcoma; and glioma ...

Abstract	Wnt signaling pathways are highly conserved cascades that mediate multiple biological processes through canonical or noncanonical pathways, from embryonic development to tissue maintenance, but they also contribute to the pathogenesis of numerous cancers. Recent studies have revealed that Wnt signaling pathways critically control the interplay between cancer cells and tumor-associated macrophages (TAMs) in the tumor microenvironment (TME) and potentially impact the efficacy of cancer immunotherapy. In this review, we summarize the evidence that Wnt signaling pathways boost the maturation and infiltration of macrophages for immune surveillance in the steady state but also polarize TAMs toward immunosuppressive M2-like phenotypes for immune escape in the TME. Both cancer cells and TAMs utilize Wnt signaling to transmit signals, and this interaction is crucial for the carcinogenesis and progression of common solid cancers, such as colorectal, gastric, hepatocellular, breast, thyroid, prostate, kidney, and lung cancers; osteosarcoma; and glioma. Specifically, compared with those in solid cancers, Wnt signaling pathways play a distinct role in the pathogenesis of leukemia. Efforts to develop Wnt-based drugs for cancer treatment are still ongoing, and some indeed enhance the anticancer immune response. We believe that the combination of Wnt signaling-based therapy with conventional or immune therapies is a promising therapeutic approach and can facilitate personalized treatment for most cancers.
MeSH term(s)	Male ; Humans ; Wnt Signaling Pathway ; Tumor-Associated Macrophages ; Neoplasms/drug therapy ; Macrophages/metabolism ; Immunotherapy ; Tumor Microenvironment
Language	English
Publishing date	2024-03-19
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	208787-x
ISSN	1873-2968 ; 0006-2952
ISSN (online)	1873-2968
ISSN	0006-2952
DOI	10.1016/j.bcp.2024.116154
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 19: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Immunotherapeutic Approaches for Glioblastoma Treatment

Nasser K. Yaghi / Mark R. Gilbert

Biomedicines, Vol 10, Iss 427, p

2022 Volume 427

Abstract: ... immunotherapy treatments, with a focus on clinical applications, and propose future directions for the field ... of GBM immunotherapy. ... disease-specific challenges for immunotherapies, both brain-related and non-brain-related, which will need ...

Abstract	Glioblastoma remains a challenging disease to treat, despite well-established standard-of-care treatments, with a median survival consistently of less than 2 years. In this review, we delineate the unique disease-specific challenges for immunotherapies, both brain-related and non-brain-related, which will need to be adequately overcome for the development of effective treatments. We also review current immunotherapy treatments, with a focus on clinical applications, and propose future directions for the field of GBM immunotherapy.
Keywords	glioblastoma ; GBM ; glioma ; radiotherapy ; surgery ; chemotherapy ; Biology (General) ; QH301-705.5
Language	English
Publishing date	2022-02-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Immunotherapeutic Approaches for the Treatment of Glioblastoma Multiforme

Suprava Das / Banendu Sunder Dash / Thejas P. Premji / Jyh-Ping Chen

International Journal of Molecular Sciences, Vol 24, Iss 10546, p

Mechanism and Clinical Applications

2023 Volume 10546

Abstract: ... different immunotherapeutic approaches currently in preclinical and clinical trials, including immune ... therapy, this review aims to discuss the mechanisms, benefits, and limitations of immunotherapy ... Glioma is one of the most aggressive types of primary brain tumor with a high-grade glioma known ...

Abstract	Glioma is one of the most aggressive types of primary brain tumor with a high-grade glioma known as glioblastoma multiforme (GBM). Patients diagnosed with GBM usually have an overall survival rate of less than 18 months after conventional therapy. This bleak prognosis underlines the need to consider new therapeutic interventions for GBM treatment to overcome current treatment limitations. By highlighting different immunotherapeutic approaches currently in preclinical and clinical trials, including immune checkpoint inhibitors, chimeric antigen receptors T cells, natural killer cells, vaccines, and combination therapy, this review aims to discuss the mechanisms, benefits, and limitations of immunotherapy in treating GBM patients.
Keywords	glioblastoma multiforme ; brain cancer ; clinical application ; immunotherapy ; Biology (General) ; QH301-705.5 ; Chemistry ; QD1-999
Language	English
Publishing date	2023-06-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Cell- and peptide-based immunotherapeutic approaches for glioma.

Yamanaka, Ryuya

Trends in molecular medicine

2008 Volume 14, Issue 5, Page(s) 228–235

Abstract: ... peptide-based immunotherapy approaches for patients with gliomas. ... approaches is essential. Recent reports demonstrate that systemic immunotherapy using dendritic cells (DCs ... or peptide vaccines is capable of inducing an antiglioma response. These approaches successfully ...

Abstract	Glioblastoma multiforme (GBM) is the most common and lethal primary malignant brain tumor. Although considerable progress has been made in surgical and radiation treatment for glioma patients, the impact of these advances on clinical outcome has been disappointing. Therefore, the development of novel therapeutic approaches is essential. Recent reports demonstrate that systemic immunotherapy using dendritic cells (DCs) or peptide vaccines is capable of inducing an antiglioma response. These approaches successfully induce an antitumor immune response and prolong survival in patients with glioma without major side effects. There are several types of glioma, so to achieve effective therapy, it might be necessary to evaluate the molecular genetic abnormalities in individual patient tumors and design novel immunotherapeutic strategies based on the pharmacogenomic findings. Here, we review recent advances in DC- and peptide-based immunotherapy approaches for patients with gliomas.
MeSH term(s)	Animals ; Antigens, Neoplasm/chemistry ; Brain Neoplasms/immunology ; Brain Neoplasms/therapy ; Clinical Trials as Topic ; Dendritic Cells/cytology ; Glioma/immunology ; Glioma/therapy ; Humans ; Immunotherapy/methods ; Models, Biological ; Models, Genetic ; Peptides/chemistry ; Peptides/therapeutic use
Chemical Substances	Antigens, Neoplasm ; Peptides
Language	English
Publishing date	2008-05
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2036490-8
ISSN	1471-499X ; 1471-4914
ISSN (online)	1471-499X
ISSN	1471-4914
DOI	10.1016/j.molmed.2008.03.003
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4345: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito